As of Oct 20
| +0.001 / +1.06%|
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 1.35, with a high estimate of 2.00 and a low estimate of 0.70. The median estimate represents a +1,318.07% increase from the last price of 0.10.
The current consensus among 2 polled investment analysts is to Buy stock in ImmunoCellular Therapeutics Ltd. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.